Biogen Patent Suit Targets Somerset’s Copy of Spinraza Therapy

Somerset Therapeutics Private Ltd.'s proposed copy of Biogen Inc.'s Spinraza infringes three patents covering the spinal muscular atrophy treatment and methods of administering it, a new federal lawsuit said.

Somerset’s proposed generic 12 mg/5 mL injection of nusinersen, Spinraza’s active ingredient, infringes US Patent Nos. 9,926,559, 10,436,802, and 12,013,403, Biogen alleged in a complaint filed Wednesday in the US District Court for the District of Delaware.

The filing doesn’t mention Spinraza’s 28 mg/5 mL and 50 mg/5 mL spinal injections, both of which the US Food and Drug Administration approved March 27.

The case appears to be ...